ALCAM and cancer: CD166 has been reported to be involved in many biological activities, such as T cell activation and proliferation, monocyte migration, axon fasciculation, angiogenesis, and hematopoiesis [16, 17], and has been suggested to be correlated with aggressive disease phenotype in many cancers including CRC [18], esophageal cancer [19], melanoma [20], breast [21], ovarian [22], and prostate [23].